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ABSTRACT 
The human zDHHC S-acyltransferase family 
comprises 23 enzymes that mediate the S-
acylation of a multitude of cellular proteins, 
including channels, receptors, transporters, 
signalling molecules, scaffolds and chaperones. 
This reversible post-transitional modification 
(PTM) involves the attachment of a fatty acyl 
chain, usually derived from palmitoyl-CoA, to 
specific cysteine residues on target proteins, 
which affects their stability, localisation and 
function. These outcomes are essential to 
control many processes, including synaptic 
transmission and plasticity, cell growth and 
differentiation, and infectivity of viruses and 
other pathogens. Given the physiological 
importance of S-acylation, it is unsurprising 
that perturbations in this process, including 
mutations in ZDHHC genes, have been linked 
to different neurological pathologies and 
cancers, and there is growing interest in 
zDHHC enzymes as novel drug targets. 
Although zDHHC enzymes control a diverse 
array of cellular processes and are associated 
with major disorders, our understanding of 
these enzymes is surprisingly incomplete, 
particularly in regards to the regulatory 
mechanisms controlling these enzymes. 
However, there is growing evidence 
highlighting the role of different PTMs in this 
process. In this review, we discuss how PTMs 
including phosphorylation, S-acylation and 
ubiquitination affect the stability, localisation 
and function of zDHHC enzymes and speculate 
on possible effects of PTMs that have emerged 
from larger screening studies. Developing a 
better understanding of the regulatory effects of 
PTMs on zDHHC enzymes will provide new 
insight into the intracellular dynamics of S-
acylation and may also highlight novel 
approaches to modulate S-acylation for clinical 
gain.  
      
Proteins are essential functional and structural 
components of living organisms, and an 
estimated 20,000 protein coding genes have 
been identified in higher organisms such as 
humans (1) and mice (2). However, direct 
expression of these genes is not sufficient to 
account for the complexity of life processes 
and additional means of extending protein 
diversity are required. This is achieved 
through alternative splicing during mRNA 
maturation and protein post-translational 
modifications (PTMs). In the case of humans, 
this allows the body to extend the proteome to 
an estimated 0.62-6.13 million different 
protein species that are necessary to sustain 
life (3).  
S-acylation represents one of over 200 different 
types of PTMs (4,5) but it has come to 
prominence recently following several major 
breakthroughs. One important advance has 
been the development of chemical biology 
methodologies that have facilitated mass 
spectrometry-based profiling of the S-acylated 
proteome in a range of different cells and 
organisms (6,7). This has revealed that over 
4,000 human and mouse proteins are S-
acylated, of which approximately 140 mouse 
and 350 human proteins have, to date, been 
validated using other techniques (8). These S-
acylated proteins include soluble signalling 
proteins, membrane receptors, ion channels, 
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transporters, molecular scaffolds and 
chaperones (9). Functional roles of S-acylation 
in all the mammalian physiological systems are 
continually being uncovered, including 
important roles in synaptic transmission and 
plasticity (10,11), cardiac electrophysiology 
(12,13), hormone release and response 
pathways (11,14), and immune cell function 
(15).  In addition, links between S-acylation and 
pathological processes are also emerging 
including in viral and bacterial infection (16), 
intellectual disability, epilepsy, schizophrenia, 
Huntington’s disease, diabetes and cancer 
(9,17-20). Indeed, recent studies have shown 
that S-acylation stabilises the immune 
checkpoint protein PD-L1, allowing cancer 
cells to evade the immune system (21). As a 
result, there is growing interest in S-acylation 
and the enzymes that control this process. 
S-Acylation involves the attachment of fatty 
acids to cysteine residues on proteins through a 
labile thioester linkage (9). The attachment of 
the palmitate (C16:0) fatty acid, known as 
palmitoylation, is the most common type of S-
acylation, although stearate (C18:0), oleate 
(C18:1), and other longer chain fatty acids can 
also be utilised, to a lesser extent (22-27). The 
attachment of these fatty acids can affect 
proteins in a variety of ways. At the simplest 
level, the hydrophobic acyl chains mediate 
membrane attachment of a variety of soluble 
proteins including Ras, Src, and G subunits 
(28). S-Acylation is also a recognised 
intracellular sorting signal that controls the 
movement of proteins through the secretory and 
endosomal networks (28). Indeed, a recent 
study suggested that S-acylation plays a central 
role in anterograde intra Golgi transport of 
newly-synthesised proteins by mediating 
enrichment of proteins in the rims of Golgi 
cisternae from where vesicle budding takes 
place (29). Targeting to the rims of the cisternae 
was suggested to reflect an intrinsic affinity of 
S-acylated proteins for curved membranes (29). 
Lateral segregation is also proposed to operate 
at other intracellular membranes as S-acylation 
appears to be a signal for protein movement into 
cholesterol-rich raft membranes (30). Other 
prominent effects of S-acylation include 
regulating protein-protein interactions or 
protein stability, the latter effect through 
interplay with ubiquitin-dependent degradation 
processes (9). 
S-Acylation is widespread in eukaryotes, and 
breakthrough studies in the yeast 
Saccharomyces cerevisiae showed that this 
process is enzyme-mediated (31,32). The 
defining feature of S-acyltransferase enzymes 
is a 51-amino acid zinc-finger cysteine-rich 
domain (CRD) that contains a catalytic DHHC 
(apartate-histidine-histidine-cysteine) 
tetrapeptide (33,34). Twenty-three of these 
“zDHHC” enzymes are present in mammalian 
species (35), and have been the subject of 
intense interest since their discovery. All 
zDHHC enzymes are predicted to contain 
between 4–6 membrane-spanning domains 
with the catalytic DHHC domain present in a 
cytoplasmic loop, and in mammalian cells these 
enzymes localise in an isoform-specific manner 
to the endoplasmic reticulum, Golgi, 
endosomes and the plasma membrane, (36-39). 
The process of S-acylation involves a two-step 
ping-pong mechanism, where the deprotonated 
and nucleophilic DHHC cysteine first 
undergoes autoacylation, followed by transfer 
of the acyl group to a cysteine residue on a 
target protein (40,41). 
A recent breakthrough study described the 
crystal structure of human zDHHC20 and 
zebrafish zDHHC15 (39,42). The structure 
revealed that the transmembrane domains of 
these enzymes form a tepee-like arrangement 
that accommodate the acyl chain of the acyl-
CoA, with the cysteine of the DHHC motif 
positioned at cytosolic face of the membrane at 
the base the cavity (39,42). The aspartate (D) 
residue of the DHHC motif acts to polarise the 
second histidine (H), which deprotonates the 
catalytic cysteine (C) to form a reactive thiolate 
nucleophile. This cysteine thiolate then attacks 
the thioester carbonyl carbon of the acyl-CoA 
molecule to form the autoacylated intermediate 
(39,42). The DHHC-CRD also contains two 
zinc fingers that coordinate two zinc ions 
(Zn2+), which are important to maintain the 
structural integrity of this domain (39,42). In 
addition, important contacts are made between 
the DHHC-CRD and conserved motifs in the C-
terminus of zDHHC enzymes (39,42). 
Following autoacylation of zDHHC enzymes, 
the acyl chain is either hydrolysed or 
transferred to a reactive cysteine in a substrate 
protein (40,41). Some zDHHC enzymes display 
a lack of substrate selectivity and modify 
accessible and reactive cysteine in a diverse 
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array of protein targets (43,44). In contrast, 
other zDHHC enzymes are highly selective and 
recognise specific domains or motifs in their 
substrate targets as an essential prerequisite to 
S-acylation (9,45). This combination of 
selectivity and promiscuity is likely essential to 
allow the S-acylation of a large and diverse set 
of cellular proteins. 
Despite growing knowledge of the substrate 
targets and physiological roles of the zDHHC 
enzyme family, the means through which these 
enzymes are regulated is poorly understood. 
However emerging evidence highlights a role 
for different PTMs in regulating several 
members of the zDHHC family. This review 
will discuss established roles of PTMs in 
regulating the stability, localisation and 
function of zDHHC enzymes, and speculate on 
the potential role of modifications identified in 
larger proteomic studies, using available 
bioinformatics and structural data. 
POST-TRANSLATIONAL 
MODIFICATIONS OF ZDHHC 
ENZYMES 
Traditional labelling and detection 
methodologies have identified PTMs that 
regulate many cellular proteins, albeit with a 
bias towards phosphorylation. Although these 
traditional approaches have been hugely 
valuable, they are time-consuming and often 
focus on detailed analysis of single sites of 
modification within a single protein of interest. 
In recent years, the vast increase in the use of -
omics technologies to investigate cellular 
processes and pathways together with 
prediction algorithms have produced a wealth 
of information on the different chemical 
modifications that have been detected or are 
predicted to occur on cellular proteins. Whilst 
this has provided a detailed catalogue of PTMs 
on any single protein, it is important to note that 
the majority of these lack validation and the 
stoichiometry of modification is unclear. The 
relative abundance of different PTMs in human 
and mouse zDHHC enzyme isoforms is 
highlighted in Figure 1A, with a focus on 
phosphorylation, ubiquitination, S-acylation, 
acetylation and methylation. Collectively, these 
types of PTM have been shown to exert a 
variety of regulatory effects on different 
proteins, including modulating protein-protein 
interactions, protein activity, stability, 
degradation and sub-cellular localisation (46-
52). Specific regulatory effects of 
phosphorylation, ubiquitination and S-
acylation on zDHHC enzymes have been 
described, whereas mechanistic effects of 
acetylation and methylation on these enzymes 
have not yet been reported (Figure 1B). 
Globally, phosphorylation represents the most 
studied PTM, which has also been found to be 
highly abundant in the human proteome (49). 
Therefore, it is not surprising that 
phosphorylation of serine, threonine, and 
tyrosine residues are prominent modifications 
of zDHHC enzymes (Figure 1A). 
Ubiquitination is also detected on many 
zDHHC enzymes, while lysine acetylation and 
S-acylation are prominent in the human and 
mouse enzyme families, respectively. The latter 
is likely a consequence of the divergent 
proteomics screening efforts that have been, to 
date, conducted in these species. In both human 
and mouse studies, arginine and lysine 
methylation of zDHHC enzymes have been 
reported less commonly (Figure 1A). Out of the 
23 zDHHC enzymes, current data suggests that 
zDHHC5 may be the most extensively 
modified, exhibiting 8 different PTM types in 
humans and 5 different PTM types in mice. In 
the human isoform, phosphorylation and 
ubiquitination are the predominant 
modifications. However, a caveat when 
comparing PTMs of different zDHHC enzymes 
is that detection will be influenced by the 
relative abundance of these enzymes in the 
source tissue. 
REGULATION OF ZDHHC ENZYMES 
BY PHOSPHORYLATION 
Phosphorylation is known to modulate a 
multitude of protein-protein interactions (49), 
and recent work showed phospho-dependent 
regulation of substrate binding by the Golgi 
enzyme zDHHC13. Specifically, 
phosphorylation of zDHHC13 at Ser8 by Ataxia 
Telangiectasia and Rad3 Related (ATR) kinase 
enhanced its interaction with the substrate 
protein Melanocortin 1 Receptor (MC1R) 
(53,54). S-acylation of MC1R is associated 
with enhanced receptor signalling, increased 
synthesis of melanin, and activation of cell-
protective DNA-repair pathways (53). 
Furthermore, enhancing the S-acylation of 
MC1R variants that are linked to red hair and 
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increased susceptibility to melanoma was 
shown to prevent melanomagenesis in mice 
(53). zDHHC13 is closely related to zDHHC17, 
and these are the only zDHHC isoforms to 
possess cytosolic N-terminal Ankyrin (ANK) 
repeat domains, which have been shown to play 
an important role in protein substrate 
recognition and binding (45). However, Ser8 is 
outside of the ankyrin-repeat domain of 
zDHHC13 (amino acids 43–277) (Figure 2), 
and thus its role in substrate binding is unclear. 
It will be important to determine the mechanism 
through which phosphorylation of this amino 
acid affects MC1R interaction and if the effect 
of this PTM extends to other zDHHC13 
substrates. For example, is Ser8 part of the 
MC1R binding site or does phosphorylation of 
this residue alter the structure or presentation of 
the ANK domain to facilitate binding? 
Interestingly, Tyr59 in zDHHC13 is also 
modified by phosphorylation (55) (Figure 2). 
This site is of particular interest as it is in the 
ankyrin-repeat domain of zDHHC13 and recent 
crystallographic data showed that the 
corresponding residue in zDHHC17 (Tyr67) is 
part of the substrate interaction site of this 
enzyme. Moreover, a tyrosine-to-alanine 
substitution resulted in a five-fold drop in the 
affinity of zDHHC17 for the SNAP25 substrate 
protein (56). As zDHHC13 also binds to 
SNAP25, it can be envisaged that the addition 
of negative phosphate moieties to Tyr59 could 
disrupt substrate interactions of zDHHC13. 
Phospho-regulation may also affect zDHHC17 
substrate interactions as several residues in this 
Golgi-localised enzyme including Tyr56, Tyr67 
and Tyr70 in the first ANK domain of 
zDHHC17, and Tyr286 in the last ANK domain 
of this enzyme have also been found to be 
phosphorylated in proteomics experiments 
(55,57) (Figure 2).  
The Golgi-localised enzyme zDHHC3  (37,43) 
has also been suggested to display phospho-
dependent regulation of substrate interactions. 
In mouse neuroblastoma N2A cells, 
phosphorylation of zDHHC3 Tyr18 by 
fibroblast growth factor (FGF) receptor and 
Tyr295/Tyr297 by Src kinase (Figure 2) was 
suggested to affect enzyme activity and 
interaction with the neuronal cell adhesion 
molecules (NCAM140/NCAM180), following 
FGF2 stimulation (58). Regulation of zDHHC3 
substrate binding is particularly interesting as 
previous work suggested that this highly active 
and promiscuous enzyme does not display 
detectable binding to at least some of its 
substrates (43). Therefore, it will be interesting 
to explore if the phosphorylation events that 
impact NCAM140/180 interaction also affect 
S-acylation of other substrates of this enzyme. 
Interestingly, these phosphorylation sites in 
zDHHC3 do not appear to be conserved in 
zDHHC7 (Figure 2), and therefore unique 
phosphorylation profiles of these highly similar 
enzymes offer potential for their differential 
regulation. 
Phosphorylation has also been suggested to 
control the trafficking of zDHHC5 and 
zDHHC2, which are localised to post-Golgi 
membrane compartments in neurons. These 
effects of phosphorylation are thought to 
involve regulated interactions of the zDHHC 
enzymes with endocytic adaptor proteins. 
Under basal conditions, zDHHC5 localises to 
dendritic spines in rat hippocampal neurons, 
where it associates with postsynaptic density 
protein 95 (PSD95) and Fyn kinase (59). Under 
these conditions, the overlap of zDHHC5 and 
its substrate -catenin is low (59). Following 
neuronal stimulation however zDHHC5 
displays a shift in localisation, which allows it 
to access and S-acylate -catenin, which 
facilitates movement of this protein to spines 
where it promotes stabilisation of N-cadherin at 
synapses, synaptic enlargement, and the 
recruitment of AMPA glutamate receptors to 
these sites (60). How does neuronal stimulation 
lead to zDHHC5 redistribution? This effect 
appears to be linked to phosphorylation of 
Tyr533, which is present within a Y533NDL 
endocytotic motif (59,60) (Figure 2). Under 
resting conditions, this site is phosphorylated 
by Fyn kinase and therefore not active (Figure 
3A). However following neuronal stimulation 
the zDHHC5-Fyn interaction is reduced, 
allowing dephosphorylation of Tyr533 and 
subsequent recruitment of the  subunit of the 
clathrin adaptor AP2, followed by clathrin-
mediated endocytosis of zDHHC5 and co-
localisation with -catenin (59,60) (Figure 3A). 
Interestingly, the C-terminal tail of zDHHC5 
appears to exhibit extensive serine and 
threonine phosphorylation (61). This hints 
towards the possible phospho-regulation of 
other facets of this enzyme, although the 
biological relevance of many of these 
modifications is yet to be established.  
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zDHHC2 also displays a dynamic localisation, 
and it was shown to cycle between recycling 
endosomes and the post-synaptic plasma 
membrane to regulate activity-dependent S-
acylation of the post-synaptic scaffold PSD95 
(36,62). Interestingly, phosphorylation may 
also regulate this dynamic cycling of this 
enzyme by affecting the efficacy of trafficking 
signals (63) (Figure 3B). Analysis of the 
localisation of mouse zDHHC2 in 
neuroendocrine PC12 cells and hippocampal 
neurons identified two potential endocytic 
signals in the C-terminal tail, which when 
mutated led to enhanced accumulation at the 
plasma membrane: i) a non-conventional 
dileucine motif (SxxxLL, where ‘x’ represents 
any amino acid) at amino acid positions 330–
335, which differs from the conventional acidic 
D/ExxxLL motif that interacts with clathrin 
adaptors; and ii) an Asn-Pro (NP) motif at 
amino acid positions 357–358 (63) (Figure 2). 
It was suggested that phosphorylation of Ser330 
in the SxxxLL motif could make this more like 
a conventional acidic dileucine motif and allow 
recognition by AP2. Indeed, introduction of a 
phospho-null mutation (alanine) at Ser330 led to 
increased abundance of zDHHC2 at the plasma 
membrane, whereas a phospho-mimetic mutant 
(aspartic acid substitution) had no effect (63). 
Interestingly, additional phospho-mimetic 
mutations introduced in the vicinity of the 
dileucine or NP motif increased the abundance 
of zDHHC2 inside the cell, suggesting that 
phosphorylation of specific sites in the C-
terminus may enhance recognition of these 
endocytic motifs by AP2, perhaps by inducing 
local conformational changes that unmask the 
endocytic sites (63). Specifically, phospho-
mimetic, but not phospho-null, substitutions at 
Ser356 and Thr361 led to an increased endosomal 
localisation of zDHHC2 and this effect required 
an intact NP motif. This suggests that 
phosphorylation of Ser356 and Thr361 might 
enhance the efficacy of the NP motif as an 
endocytic signal. In contrast, the enhanced 
endosomal localisation of zDHHC2 carrying 
phospho-mimetic substitutions of Ser344/Ser345 
or Thr340/Thr342 was dependent on an intact 
dileucine motif, suggesting that 
phosphorylation of these residues enhance this 
endocytic signal (Figure 3B). The key serine of 
the SxxxLL motif (Ser330) has been reported as 
a phosphorylation site in a single 
phosphoproteome study of mouse pancreatic 
cells, whereas modification of Ser341 and Ser357 
in human zDHHC2, which are present at the 
same position as Thr340 and Ser356 in mouse 
zDHHC2, have been identified in multiple mass 
spectrometric studies (64-67) (Figure 2).  
In addition to zDHHC2 and zDHHC5, a 
number of other human zDHHC enzymes 
possess sequences that are similar to the 
aforementioned endocytotic signalling motifs. 
Specifically, zDHHC8 contains C-terminal 
478SxxxLL and 541YDNL sequences, with mass-
spectrometric evidence of phosphorylation 
within the vicinity of these sites, including at 
Tyr541 of the YDNL sequence (68-72). 
zDHHC5, zDHHC14, zDHHC15 and 
zDHHC20 all contain C-terminal SxxxLL 
sequences (469SYDSLL, 446SPPRLL, 
303SQNPLL and 330SKNRLL, respectively), 
with reported phosphorylation at Ser446 in 
zDHHC14 and Ser330 of zDHHC20 
(54,66,67,73,74) (Figure 2). Therefore, it is 
possible that regulation of S-acyltransferase 
enzyme localisation though C-terminal chain 
phosphorylation is not only limited to zDHHC2 
and zDHHC5, but could in fact be a more 
widespread phenomenon amongst the zDHHC 
enzyme family. However, as in previous cases, 
validation of many of these reported 
phosphorylation sites using techniques other 
than mass-spectrometry is still required.     
Analysis of other reported phosphorylation 
sites in zDHHC enzymes highlights further 
potential for structural/conformational 
regulation. The C-terminal Thr-Thr-x-Glu 
(TTxE) motif, where ‘x’ represents any amino 
acid, is a conserved feature of zDHHC enzymes 
(34) (Figure 2). Human zDHHC20 enzyme 
structural data revealed that this motif lies in 
close proximity to the catalytic DHHC 
tetrapeptide, where the conformation is 
stabilised through hydrogen bonding between 
the second threonine of the TTxE motif (Thr241) 
and the aspartate of the catalytic DHHC 
tetrapeptide (Asp153) (39) (Figure 3C). 
Importantly, alanine substitution of the two 
threonine amino acids to form an AAxE mutant 
was associated with a marked reduction in 
enzymatic activity (39). Some zDHHC 
enzymes possess an analogous Thr-Ser-x-Glu 
(TSxE) motif, where a similar stabilising 
hydrogen bonding interaction between the 
serine and the DHHC aspartate can be predicted 
(Figure 3D). Interestingly, there is proteomics 
evidence to support the phosphorylation of 
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Ser552 in the TSxE motif of human zDHHC13 
(Figure 2). It is possible that this modification 
could alter the conformation of the enzyme by 
disrupting the interaction between the TSxE 
and DHHC motifs, thereby affecting the 
enzymes catalytic activity (as seen with the 
AAxE mutant of zDHHC20). This hypothesis 
was strengthened by modelling a 
phosphothreonine PTM into the zDHHC20 
crystal structure TTxE motif. This model shows 
that hydrogen bonding between Asp153 and the 
phosphorylated form of Thr241 appears to be 
precluded (Figure 3E). Thus, phosphorylation 
of the TSxE motif in zDHHC13 might be a 
novel mechanism of enzyme regulation, 
although further experiments are required to 
validate this phosphorylation site and the 
possible effects of this modification on 
zDHHC13 activity. 
It is clear that phosphorylation of zDHHC 
enzymes can be associated with a broad range 
of regulatory effects. This section has focused 
on reported effects of phosphorylation on 
substrate interactions of zDHHC13 and 
zDHHC3 and dynamic trafficking of zDHHC2 
and zDHHC5, and highlighted where these 
effects might extend to related enzymes. In 
addition, we provided a more speculative 
example of potential phospho-regulation of the 
TSxE motif in zDHHC13 and its effects on 
intramolecular interactions with the DHHC 
domain of this enzyme. However, these 
discussions have covered only a fraction of the 
total residues and zDHHC enzymes that have so 
far been reported as modified by this PTM type. 
The effect of the majority of these 
phosphorylation modifications on zDHHC 
enzymes is still unknown, and this represents a 
major knowledge gap, highlighting the need for 
further research in the area.     
REGULATION OF ZDHHC ENZYMES 
BY S-ACYLATION 
Several zDHHC enzymes have been reported to 
undergo S-acylation outside of their catalytic 
DHHC cysteine. The role of this S-acylation as 
a regulatory modification has been most 
extensively studied for zDHHC6 using a 
combination of kinetic measurements of protein 
and S-acylation half-life of wild-type and 
cysteine mutant zDHHC6 combined with 
mathematical modelling. zDHHC6 is S-
acylated by zDHHC16 on three cysteine 
residues that lie within the soluble cytosolic C-
terminal tail of the enzyme, namely Cys328, 
Cys329, and Cys343 (75,76) (Figure 2). 
Interestingly, S-acylation of each cysteine turns 
over with different kinetics, and these 
modifications differentially affect catalytic 
activity and protein stability (Figure 4). 
Specifically, single S-acylation of cysteine 
Cys328 of zDHHC6 leads to a substantial 
reduction in protein half-life (5 hours versus 40 
hours for non-acylated protein) that is 
pronounced further when the other two 
cysteines are also modified (protein half-life of 
0.3 hours) (77). zDHHC6 S-acylated at Cys328 
is rapidly degraded by the ubiquitin-dependent 
endoplasmic reticulum associated degradation 
(ERAD) pathway or converted to a different 
species by acyl-protein thioesterase 2 (APT2) 
mediated deacylation (77). In contrast, single S-
acylation at Cys329 enhances zDHHC6 stability 
by 2.5-fold, whereas single modification of 
Cys343 leads to around a two-fold reduction in 
half-life (77). Intriguingly, although Cys328-
modified zDHHC6 displays rapid S-acylation 
and protein turn-over kinetics, modification of 
this site generates a highly-active form of the 
enzyme (77). The exact mechanism behind 
these site-specific modulating effects is 
unknown, but it is worth noting that a number 
of proteomics studies have detected zDHHC6 
ubiquitination in the C-terminal domain at 
Lys245, Lys273, Lys336, Lys353, and Lys371 (78-80) 
(Figure 2). Furthermore, zDHHC6 displayed 
enhanced ubiquitination when the thioesterase 
APT2 was depleted, highlighting a link 
between S-acylation and ubiquitination of the 
S-acyltransferase (77). The ERAD pathway 
requires transmembrane proteins to be 
polyubiquitinated, and it is possible that S-
acylation of Cys328 in the flexible cytosolic C-
terminus promotes E3 ligase access to the 
ubiquitination sites. This enhanced 
ubiquitination could be facilitated by a shift in 
the distribution of zDHHC6 in the 2D space of 
the ER membrane or by changes in the 
oligomeric state of the enzyme, as both of these 
parameters were shown to be affected in S-
acylation-null mutants of zDHHC6 (77). The 
positive correlation between S-acylation of 
Cys328 and enhanced degradation of zDHHC6 is 
interesting as many proteins display higher 
ubiquitination and degradation when their S-
acylation is inhibited (9). 
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In addition to the three S-acylated cysteines in 
the C-tail of zDHHC6, analysis of site-specific 
S-acylation in mouse forebrain identified C-
terminal S-acylation sites in an additional seven 
enzymes (75). Interestingly, five of these 
enzymes (zDHHC-5, -8, -16, -17 and -20) are 
modified in a conserved GCxxN motif (75,76). 
Several recent studies have shown that the C-
terminal S-acylated cysteines in zDHHC5 
(Figure 2) are important in regulating the 
distribution of this enzyme between the plasma 
membrane and internal membranes in non-
neuronal cells (81-83). Indeed, one study 
reported that S-acylation of these cysteines 
occurred in response to isoproterenol 
stimulation, leading to stabilisation of zDHHC5 
at the plasma membrane (81). As the C-tail of 
zDHHC5 is also S-acylated in brain, it will be 
interesting in future work to investigate the 
interplay between S-acylation and 
phosphorylation of the YDNL endocytic motif 
in regulating activity-dependent trafficking of 
this enzyme in neurons. 
In addition to regulating the stability and 
localisation of zDHHC enzymes, might S-
acylation also directly affect S-acyltransferase 
activity? Within the zDHHC enzyme CRD, six 
highly conserved cysteines together with two 
histidine residues form the two zinc finger 
domains that are involved in coordinating Zn2+. 
These zinc finger domains conform to a Cys-
Cys-His-Cys (CCHC) structure, each 
interacting with a Zn2+ ion in a tetrahedral 
coordination geometry (39,84,85). Based on 
experimental and computational data acquired 
from zinc finger bearing proteins with a similar 
CCHH arrangement (86,87), it is presumed that 
Zn2+ binding contributes to the correct folding 
of zDHHC enzymes during their biosynthesis. 
In addition to ensuring correct protein folding, 
these Zn2+ ions are also believed to be 
responsible for maintaining the structural 
stability of S-acyltransferase enzymes and for 
the favourable positioning of the catalytic 
DHHC cysteine towards the hydrophobic 
tepee-like pocket formed by the TMDs, where 
acyl-CoA engagement takes place (39). 
Moreover, such zinc-binding domains are also 
known to act as protein recognition motifs, and 
it is therefore possible that they also play some 
role in substrate binding. 
A study by the Linder group employed a mass 
spectrometry approach to detect S-acylation of 
mouse zDHHC3 expressed and purified from 
insect cells. Almost complete coverage of 
peptides from the CRD was achieved using this 
approach and S-acylation was reproducibly 
detected on Cys146 (85) (Figure 2). 
Furthermore, mutation of this residue caused a 
marked loss of S-acylation of zDHHC3 (85). 
Intriguingly, Cys146 is predicted to be involved 
in Zn2+ coordination based on structural and 
sequence data of the human zDHHC20 enzyme. 
The importance of Cys146 and other cysteines 
linked to Zn2+ coordination in zDHHC3 was 
revealed through their individual substitution 
with serine residues, which perturbed the 
structural integrity of the enzyme and inhibited 
S-acyltransferase activity (85). The authors of 
this study noted the caveat that as Zn2+ binding 
is coupled to correct folding of zDHHC 
enzymes, any mis-folding (e.g. due to high-
level overexpression) could allow S-acylation 
of cysteines that are normally unavailable for 
such modification (85). Nevertheless, S-
acylation has also been detected at Cys161 of 
zDHHC9 in mouse forebrain (75) (Figure 2), 
which is also linked to Zn2+ coordination and 
present within a different CCHC zinc finger to 
Cys146 of zDHHC3.  
In summary, there is convincing evidence from 
research on zDHHC5 and zDHHC6 that S-
acylation of C-terminal cysteines can impact 
the stability, localisation and/or activity of 
zDHHC enzymes. Furthermore, as several 
zDHHC enzymes contain conserved S-
acylation sites, the effects of this PTM may 
extend to other members of the zDHHC family. 
Research showing that cysteines involved in 
zinc coordination can also be targets for S-
acylation suggest potentially intriguing 
mechanisms whereby this modification could 
directly affect enzyme structural integrity and 
activity. However, further work is required to 
determine if S-acylation of these zinc-
coordinating cysteines is physiologically 
relevant. 
REGULATION OF ZDHHC ENZYMES 
BY UBIQUITINATION 
Despite being one of the more prominent PTMs 
exhibited by the zDHHC enzyme family, the 
literature investigating effects of ubiquitination 
on S-acyltransferases is limited. As discussed 
above, there is evidence that the extent of S-
acylation of zDHHC6 could affect 
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ubiquitination of specific lysines, and 
subsequent enzyme degradation via ERAD 
(77). In this case, it will be interesting to 
explore how arginine substitutions of some of 
these lysines affect the half-life of zDHHC6 
wild-type and cysteine mutant proteins. 
The zDHHC9 enzyme can form a complex with 
the accessory protein GCP16, which was shown 
to be important in stabilising the S-
acyltransferase and preventing its degradation 
(88). This effect may be linked to ubiquitination 
as a study using the analogous yeast 
(Saccharomyces cerevisiae) protein complex 
pair Erf2-Erf4 showed a similar stabilising 
effect, with the half-life of Erf2 decreasing by 
approximately six-fold in an Erf4 mutant strain 
(89). Using His6-tagged ubiquitin, it was shown 
that Erf2 was polyubiquitinated in the Erf4 
mutant (89). Ubiquitination was blocked when 
six lysine residues within the 59 amino acid C-
terminus of Erf2 (Lys304, Lys311, Lys316, Lys335, 
Lys355 and Lys358) were mutated to arginines 
(89). Furthermore, disruption of components of 
the ERAD system in the Erf4 mutant strain led 
to an increase in Erf2 half-life, suggesting that 
ubiquitination targets Erf2 for destruction via 
the ERAD pathway (89). It was proposed that 
Erf4 imparts stability on Erf2 by masking these 
ubiquitination sites, either directly through 
binding to the C-terminal domain, or indirectly 
by binding to other regions of the protein and 
imposing conformational changes in the 
terminal chain (89). The observed stabilising 
effects of GCP16 on zDHHC9 may also reflect 
interplay with the ubiquitination machinery. 
Indeed, mass-spectrometric screens of two 
human cell lines identified C-terminal 
ubiquitination of zDHHC9 at Lys267 and Lys281 
(78) (Figure 2), the latter of which is 
homologous to the putative Erf2 Lys316 
ubiquitination site. It will be interesting to 
explore if modification of these sites in 
zDHHC9 are affected by GCP16 depletion. 
Interestingly, the ubiquitinated Lys281 of 
zDHHC9 lies within the palmitoyl conserved 
C-terminus (PaCCT) motif  that has been 
shown to be important for S-acyltransferase 
catalytic activity (39,90). The corresponding 
lysine in zDHHC20 (Lys265) has also been 
reported to undergo ubiquitination (80), and the 
crystal structure of zDHHC20 revealed that this 
lysine forms part of the enzyme’s amphipathic 
’2 helix. This helix makes contacts with 
TMD3 and TMD4, which play an important 
role in accommodating the acyl chain within the 
transmembrane tepee cavity and also contribute 
to acyl chain specificity (24,39). The ’2 helix 
is stabilised via hydrogen bonding between 
Asn266, and Ser260 and Leu261,  and disruption of 
the helix by mutation of Asn266 to alanine was 
shown to reduce activity of zDHHC20 (39). 
Therefore, in addition to the well-established 
role of ubiquitination in mediating protein 
degradation, it is plausible that the addition of a 
bulky 8.6 kDa ubiquitin to zDHHC9 Lys281 and 
zDHHC20 Lys265 residues could also perturb 
catalytic activity through disruption of the ’2 
helix structure. 
Lysine ubiquitination has also been reported in 
the vicinity of other critical domains of human 
S-acyltransferases, such as the zDHHC2 and 
zDHHC20 SxxxLL motif (78,91,92), the 
zDHHC5, zDHHC6, zDHHC7 and zDHHC8 
TTxE motif (54,78-80,91-95), and the 
zDHHC7, zDHHC16 and zDHHC20 zinc-
binding CRD (80) (Figure 2). Again, it is 
possible that conformational changes of these 
other motifs induced by ubiquitination may 
have an effect on the trafficking and activity of 
these enzymes, or that ubiquitination could 
impart direct effects on enzyme localisation. 
Conversely, changes in protein interactions at 
these sites or conformational changes (e.g. 
linked to mis-folding) could expose lysine 
residues for ubiquitinatin. 
In summary, analysis of Erf2-Erf4 has clearly 
shown an important role for interplay between 
accessory protein binding and ubiquitination-
mediated zDHHC enzyme degradation, and by 
analogy this may also operate for 
zDHHC9/GCP16. In addition, interplay 
between ubiquitination and S-acylation is 
central to stability of the zDHHC6 enzyme. The 
detection of ubiquitination on other zDHHC 
enzymes suggests a wider role for this 
modification in controlling zDHHC 
degradation. In addition, as ubiquitination often 
occurs in regions of zDHHC enzymes linked to 
activity and trafficking, this PTM could also 
impact other aspects of zDHHC biology either 
by disrupting the integrity of important 
sequences or motifs or by directly affecting 
enzyme localisation. Further research is 
required to explore these potential regulatory 
effects. 
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REGULATION OF ZDHHC ENZYMES 
BY METHYLATION AND 
ACETYLATION 
A number of unpublished (96-108) and 
published (51,109-113) mass-spectrometric 
experiments have identified several 
methylation and acetylation modifications of 
zDHHC enzymes. Although little is known 
about the role of these modifications, their 
potential for zDHHC enzyme regulation will be 
discussed briefly. 
A peptide array methylation experiment 
revealed that zDHHC8 is a substrate for the 
SET7/9 (KMT7) protein lysine 
methyltransferase in humans (114). By 
mutating putative lysine methylation sites to 
arginines, Lys300 was identified as the residue in 
zDHHC8 that was modified by SET7/9. 
Although this methylation site does not occur in 
established regulatory domains of zDHHC8 
(Figure 2), it will be of interest to determine the 
effects of this modification on the localisation, 
stability and activity of this enzyme. 
Lysine acetylation can stabilise proteins by 
either directly competing with ubiquitination or 
inducing conformational changes that obstruct 
access to ubiquitin E3 ligases (46). 
Interestingly, human zDHHC3 Lys121 and 
zDHHC5 Lys97 have been shown to be both 
acetylation and ubiquitination sites in separate 
proteomics studies (54,79,80,91,93,103,115) 
(Figure 2), which hints towards possible 
competitive regulation of stability of these 
enzymes. Paradoxically, lysine acetylation has 
also been reported to drive protein degradation 
by aiding the recruitment of third-party proteins 
that can in turn facilitate ubiquitination (46). 
Indeed, zDHHC3 and zDHHC5 can also be 
acetylated (102,103,115,116) and ubiquitinated 
(54,78-80,91-95) at a number of independent 
sites, and it is plausible that lysine acetylation 
could play a role in driving ubiquitination of 
these enzymes by protein recruitment. It is 
worth noting that methylation has also been 
implicated in either stabilising proteins or 
promoting their degradation, and such effects 
should not be disregarded in methylated 
zDHHC enzymes. Moreover, methylation and 
acetylation of amino acids can alter their 
properties in a manner that makes new 
interactions possible (50,51), and it is plausible 
that this could facilitate binding of protein 
substrates to the S-acyltransferases.  
In summary, although zDHHC8 lysine 
methylation has been confirmed experimentally 
and the modifying enzyme identified, the 
functional relevance of acetylation and 
methylation of any zDHHC enzyme is not yet 
known (Figure 1B). However, given that 
several zDHHC enzymes are modified (Figure 
1A), exploring the effects of methylation and 
acetylation is expected to reveal new insight 
into the regulatory effects of these PTMs on 
zDHHC enzymes.   
 
PERSPECTIVE 
Although our understanding of how zDHHC 
enzymes are regulated has lagged behind our 
appreciation of the substrate targets and cellular 
functions of zDHHC enzymes, there is 
emerging evidence showing important 
regulatory effects of PTMs (Figure 1B). These 
PTMs affect many aspects of zDHHC enzyme 
biology, including trafficking, localisation, 
substrate binding, activity and 
stability/degradation. However, this is likely to 
represent only the top of the iceberg. The 
available PTM proteome datasets combined 
with improved understanding about the 
structure-function relationship of zDHHC 
enzymes provides a wealth of information that 
can help generate a much better understanding 
of regulatory mechanisms controlling this 
important class of enzymes. 
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Figure 1. Post-translational modifications of zDHHC enzymes. (A) Percentage of the primary isoforms 
of the 23 zDHHC human and mouse enzymes for which the listed post-translational modifications have 
been reported. (B) Regulatory effects on zDHHC enzymes of the post-translational modifications 
discussed in this review. Data were obtained by searching the PhosphoSitePlus (61), dbPTM (117), and 
SwissPalm (8) online databases. All included modifications are supported by at least one experimental 
dataset. The synthetic ubiquitin structure (1OGW) (118) was obtained from the RCSB Protein Data 
Bank (119). P = phosphorylation; ac = acetylation; ub = ubiquitination; m1 = mono-methylation; m2 = 
di-methylation; acyl = acylation.  
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Figure 2. Diagram representing domains and motifs of selected zDHHC enzymes, and key post-
translational modifications and the residues modified. Post-translational modification data were 
obtained by searching the PhosphoSitePlus (61), dbPTM (117), and SwissPalm (8) online databases. All 
included modifications are supported by at least one experimental dataset.  Ac = acetylation; Me = 
methylation P = phosphorylation; Pal = palmitoylation; Ub = ubiquitination; AR = Ankyrin repeat 
domain; CRD = cysteine-rich domain; PaCCT = palmitoyl conserved C-terminus; TMD = trans-
membrane domain; x = any amino acid; h = human; m = mouse; and r = rat.  
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Figure 3. Phospho-regulation of zDHHC enzymes. (A) Effects of phosphorylation on zDHHC5 
localisation and substrate interaction. Under basal conditions, zDHHC5 is localised to neuronal spines 
in a complex with PSD95 and Fyn kinase, while -catenin is predominantly localised to neuronal shafts. 
Fyn kinase phosphorylates zDHHC5 Tyr533 in the C-terminal YDNL motif, which prevents binding of the 
endocytic AP2 adaptor protein. Following neuronal stimulation, Fyn kinase is inactivated and the 
zDHHC5-PSD95-Fyn complex dissociates. In the absence of Tyr533 phosphorylation, AP2 is able to bind 
to zDHHC5 (1) and the S-acyltransferase then undergoes endocytosis (2). zDHHC5 is then translocated 
 21 
 
to neuronal shafts (3), where it is able to S-acylate -catenin (4). Both zDHHC5 and modified -catenin 
are then trafficked to neuronal spines (5), where the two proteins co-localise. For clarity, S-acylation 
is only shown on delta-catenin (although PSD95, Fyn kinase and zDHHC5 also undergo S-acylation).” 
(B) Effects of phosphorylation on zDHHC2 localisation. In its non-modified form, zDHHC2 is primarily 
localised to post-synaptic membranes and undergoes minimal endocytotic cycling. However, 
phosphorylation of specific C-terminal residues between SQSHLL and NP motifs (Ser341 and Ser357 in 
human zDHHC2, and Thr340 and Ser356 in mouse zDHHC2), and the SQSHLL motif serine residue (Ser330 
in mouse zDHHC2) (1) facilitates recruitment of endocytotic adaptor proteins (2), which is proceeded 
by endocytosis (3-4) and reduced membrane abundance of zDHHC2. This trafficking of zDHHC2 allows 
access to its substrate protein PSD95. (C-E) Modelling effects of phosphorylation in the TTxE motif of 
zDHHC20. (C) The crystal structure of the human zDHHC20 (6BMM) enzyme (39), which was obtained 
from RCSB Protein Data Bank , showing the catalytic cysteine (C156), and hydrogen bonding (arrow) 
between the DHHC aspartate (D153) and the C-terminal TTxE threonine (T241). (D) Predicted 
hydrogen bonding (arrow) between the DHHC aspartate (D153) and the TSxE serine (S241) in a 
zDHHC20 T241S mutant. (E) Predicted structure of the zDHHC20 enzyme bearing a phosphothreonine 
(T241-P). The non-standard CME156 residue in the 6BMM structure was point-mutated to Cys156 as per 
the zDHHC20 6BMN structure (39). The post-translational modification was introduced into the 
zDHHC20 crystal structure using the AmberTools 18.0 software package and the FFPTM forcefield 
(120). The modified structure underwent energy minimisation, and all models were visualised using 
the Discovery Studio 2020 software.    
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Figure 4. Representation of the three main forms of S-acylated zDHHC6, and the effects of these 
modifications. zDHHC6 is localised to endoplasmic reticulum membranes (ER), where the non-acylated 
enzyme (1) is inactive and exhibits moderate protein stability. S-acylation of zDHHC6 on the single C-
terminal Cys328 by zDHHC16 affords a highly active enzyme (2) that undergoes both rapid protein 
degradation and APT2-mediated deacylation. S-acylation of zDHHC6 at Cys329 alone (3) or Cys329 and 
Cys343 (4) affords a moderately active and highly stable enzyme. S-acylation of zDHHC6 also results in 
changes to the oligomeric state and ER distribution of the enzyme (depicted by dashed arrows).     
 
